
AnaptysBio (ANAB) Stock Forecast & Price Target
AnaptysBio (ANAB) Analyst Ratings
Bulls say
AnaptysBio is a promising biotechnology company with multiple drug candidates in the pipeline, such as rosnilimab and ANB032, which have shown positive results in clinical trials for various autoimmune and inflammatory diseases. The company's strategic partnerships and strong financial position, with a cash and cash equivalents balance of $395.7 million as of December 2020, provide them with the necessary resources to continue their research and development efforts. However, there are risks associated with potential regulatory hurdles and competition in the market. Overall, AnaptysBio's innovative approach and solid financial foundation make it an attractive investment for those seeking long-term growth potential in the biotech industry.
Bears say
AnaptysBio is currently facing several key risks that could significantly impact the company's future revenue potential. These risks include ongoing litigation with GSK over the Jemperli royalty stream, potential slowdown in commercial uptake of Jemperli, increased competition in the PD-1/PD-L1 market, and potential disappointing clinical trial results. Additionally, the company's revenue is heavily reliant on Jemperli, with no other product candidates approved for commercialization. If any of these risks were to materialize, it could lead to a significant decrease in the company's revenue and overall valuation.
This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.
AnaptysBio (ANAB) Analyst Forecast & Price Prediction
Start investing in AnaptysBio (ANAB)
Order type
Buy in
Order amount
Est. shares
0 shares